SeqOne key facts
as of Oct 2026- Developer of a genomic analysis platform designed to offer analysis of genomic data.
- SeqOne is valued at approximately $101.4M as of Oct 2026 (last reported valuation).
- It has raised $48.9M; the latest was Later Stage VC ($22.6M) in May 2025.
- Notable investors include Bpifrance, Elaia Partners, Supernova Invest, IRDI Capital Investissement, Omnes Capital — 12 tracked in total.
- Status: Privately Held (backing).
SeqOne's last reported valuation, May 2025. Nothing priced has surfaced since.
- ·The complete investor list: 12 names
- ·Watch SeqOne: the Monday email on marks, rounds and moves
SeqOne funding rounds
No funding rounds for SeqOne are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs SeqOne
12+SeqOne valuation
SeqOne's last reported valuation was $101 million in May 2025. No priced round, secondary trade or fund mark has surfaced since.
SeqOne investors
12 investors are on record for SeqOne, including Bpifrance, Elaia Partners, Supernova Invest and IRDI Capital Investissement. By type, the record holds 2 venture capital firms, 2 private equity firms and 1 family office.
About SeqOne
Developer of a genomic analysis platform designed to offer analysis of genomic data. The company's platform provides advanced genomic analysis tools that manage the entire process of analysis from raw data to the final report, enabling healthcare professionals to analyze next-generation sequencing (NGS) genomic data better and cost-effectively.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2017
- Employees
- 106
- Website
- seqone.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.